NCT01955837 - Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

February 16, 2016

Study Completion Date

June 30, 2016

Conditions

Colorectal Cancer

Interventions

DRUG

TAS-102

TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

DRUG

Placebo

Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Trial Locations (4)

10330

Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok

100142

Peking University Cancer Hospital, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

138-736

Asan Medical Center, Seoul

All Listed Sponsors

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY